<DOC>
	<DOC>NCT00764036</DOC>
	<brief_summary>The purpose of this study is to evaluation the tolerability of an add-on therapy with artesunate with a duration of 4 weeks in patients with advanced breast cancer.</brief_summary>
	<brief_title>Study of Artesunate in Metastatic Breast Cancer</brief_title>
	<detailed_description>Additional objectives are: - parallel sampling of blood and saliva for the determination of drug concentrations and pharmacokinetic parameters in a substudy on the day of first application and during steady state - attempt to establish a therapeutical drug monitoring - collection of further safety data during prolonged add-on treatments (compassionate use)</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Patients with histologically or cytologically confirmed breast cancer Distant metastases or locally advanced breast cancer Age ≥ 18 years ECOG performance ≤ 2 Life expectancy of at least 6 months Written informed consent individual standard therapy according to guidelines Oral intake of trial medication possible Compliance with study procedures Women of childbearing potential: negative pregnancy test before start of medication Use of a highly effective method of birth control during intake of addon therapy for women of childbearing potential being sexually active Inclusion Criteria for Extended Treatment Phase: Participant of the phase I study ARTIC M33/2 who had tolerated the study medication for 4±1 weeks without clinically relvant adverse events or after improvement to ≤ grade 2 Participant of the phase I study ARTIC M33/2 with possible benefit by continuation or restart of the addon therapy after a next progression according to current scientific knowledge Written informed consent for extended treatment phase Consent of the responsible oncologist Compliance for further intake and followup expected Inclusion Criteria for Individual Compassionate Use: Participant of the phase I study ARTIC M33/2 Available standard therapies have minimal or only short activity or intolerable side effects Written informed consent for compassionate use Consent of the responsible oncologist Allergy to artesunate or to other artemisinin derivatives Concurrent conditions interfering with patient safety Communication problems Concurrent participation in another clinical trial or 4 weeks prior to recruitment Participation in a clinical trial with an unapproved drug 6 months prior to recruitment Sinus bradycardia, bradyarrhythmia AVBlock II° and III° QTc &gt; 500 msec Previously known long QTsyndrome Concurrent intake of a medication with clinically relevant neurotoxicity or during 30 days prior to recruitment Relevant neurological symptoms which might complicate the evaluation of the compatibility of the IMPD (f. e. cerebral metastases) or might be subject to worsening during intake of the IMPD Radiotherapy 2 weeks prior of the intake of the IMPD Concurrent intake of supplements or any other medication with unapproved efficacy f.e. vitamins, minerals or others (OTC) Pregnancy and lactation Ineffective mode of contraception in women of childbearing potential Exclusion Criteria for Extended Treatment Phase: Clinically relevant adverse Events during the first 4 weeks of intake of study medication possibly, probably or definitely related to the study medication Intolerable health risks by continuation reexposition with the study medication Continuation or reexposition is medically not acceptable after consultation of physicians responsible for their standard therapy Exclusion Criteria for Individual Compassionate Use: Intolerable health risks by reexposition with the study medication</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>phase I</keyword>
	<keyword>safety</keyword>
</DOC>